This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Amarin: Fish-Oil Pill Delivers Strong Results

(Updates stock price.)

MYSTIC, Conn. ( TheStreet) -- Amarin's (AMRN) medicinal-grade fish oil drug AMR101 significantly lowered triglyceride levels without raising "bad" LDL cholesterol, according to results of late-stage study reported Monday.

Amarin said AMR101 met all the efficacy and safety endpoints in the phase III study and as a result, the company will seek U.S. approval next year instead of in 2012 as had been in expected.

Amarin shares were up about 62% to $5.75 in early Monday's trading.

AMR101 is an ultra-purified form of the omega-3 fatty acid known as Ethyl EPA.

The phase III study known as "MARINE" enrolled patients with very high triglyceride baseline levels above 500 mg/dl and treated them with two doses of AMR101 or a placebo for 12 weeks. Twenty-five percent of the patients were also on background cholesterol-lowering statin therapy.

Patients treated with the 4 grams/day (high dose) of AMR101 showed a median triglyceride reduction of 33% compared to placebo. Patients treated with the 2 grams/day (low dose) of AMR101 had a 20% reduction in triglycerides compared to placebo. The reductions in both groups were statistically significant.

Patients entered the AMR101 study with median baseline triglyceride levels ranging from approximately 650 mg/dl to 700 mg/dl. Doctors generally consider normal triglyceride levels to be around 150 mg/dl or lower.

GlaxoSmithKline (GSK - Get Report) markets a prescription fish oil drug known as Lovaza that demonstrated a 45% reduction in triglyceride levels, according to the drug's label. While this appears superior to AMR101, the baseline triglyceride level of patients in the pivotal Lovaza study was around 800 mg/dl -- higher than it was in Amarin's MARINE study.

Amarin says AMR101 was even more effective for a subset of patients in the MARINE study with baseline triglycerides in the 900-1,000 mg/dl range, or comparable to patients described in the Lovaza label.

For these patients, treatment with the high dose of AMR101 led to a 45% reduction in triglycerides.

Treatment with AMR101 also did not result in a statistically significant increase in levels of LDL or "bad" cholesterol compared to placebo Patients treated with the high and low doses of AMR101 reported a 2.3% drop and a 5.2% increase in LDL cholesterol, respectively, verus placebo.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AMRN $1.31 -5.10%
GSK $39.12 -4.00%
AAPL $94.11 0.10%
FB $99.62 -4.30%
GOOG $670.81 -1.90%


Chart of I:DJI
DOW 15,892.89 -312.08 -1.93%
S&P 500 1,846.54 -33.51 -1.78%
NASDAQ 4,271.0420 -92.1020 -2.11%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs